Advertisement


Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Advertisement